MedTrace Logo

DDI Study Between Dorzagliatin and Rifampicin

NCT04080609 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-09-06

No results posted yet for this study

Summary

The purpose of this drug-drug interaction study is to investigate the impact of rifampicin on the pharmacokinetics of Dorzagliatin.

Conditions

  • Drug Interaction

Interventions

DRUG

Dorzagliatin

GKA currently under clinical development

Sponsors & Collaborators

  • Hua Medicine Limited

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-27
Primary Completion
2018-04-17
Completion
2018-04-17
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04080609 on ClinicalTrials.gov